SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

New 24-month HOPE-3 extension data presented at the World Muscle Society showed slower upper-limb decline among Duchenne patients treated with deramiocel, renewing optimism ahead of the FDAs decision on the therapy. Traders see the results as supportive, though some question whether they resolve the FDAs prior statistical concerns; short-squeeze claims remain speculation.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is drawing attention as traders position ahead of fiscal Q1 earnings, hoping for evidence of data-center execution or new lease and readiness updates. Bulls cite its AI infrastructure pipeline, while skeptics focus on the prolonged share-price decline, potential dilution, executive compensation and whether contracted business will translate into shareholder value.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs recent advance and repeated tests of technical resistance dominate discussion, with bullish traders speculating about short covering and anticipating Anktiva updates, including BCG-naive data and a bladder-cancer label expansion. Others warn the gains may fade; claims of deliberate price suppression remain unverified.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Rising Treasury yields and Fed rate-hike concerns are weighing on the Russell 2000, with traders pointing to small caps greater debt and refinancing sensitivity as they lag large-cap tech. The discussion is mostly bearish over continued weakness and possible tests of key support, though some traders see oversold conditions or cooler inflation data as reasons to expect a rebound.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods product summit unveiled AI trading agents, expanded-hours and weekend stock trading, prediction-market contracts, perpetual futures, and Robinhood Social, prompting debate over whether the platform expansion can drive growth or mainly encourages riskier trading. Traders are broadly discussing the sharp price swings around the announcements, with some praising the new features and others calling the presentation underwhelming or suspecting a sell-the-news move.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels new Phase 2 PrTK05 biomarker findings showing T-cell activation are drawing attention as supportive evidence for CAN-2409 ahead of the planned Q4 2026 prostate-cancer BLA submission. Some traders view the data as strengthening the regulatory case, while others question the limited dataset and remain concerned about filing execution and the CEOs share sale.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

A sharp, high-volume selloff and reported analyst price-target reduction have prompted questions about VSTs weakness. Some traders view the pullback as a buying opportunity near support, while others are frustrated that the stock continues to fall despite the AI and data-center power-demand thesis.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

A judges pause in the broader cannabis rescheduling case has delayed the next step toward Schedule III for adult-use marijuana, weighing on Trulieve shares. Traders are split between calling the selloff an overreaction and buying the dip, noting that the paused case concerns broader rescheduling while qualifying medical cannabis has already been moved to Schedule III.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Citis downgrade to Sell, citing valuation after Modernas sharp rally on positive Phase 3 melanoma-vaccine results, is weighing on shares. Traders are divided between concerns that the oncology optimism is overextended and bullish views that the upcoming full trial data and broader mRNA cancer platform could support further gains.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategys reported Bitcoin purchase and ongoing ATM share issuance are in focus as MSTR swings with Bitcoin. Bulls view adding BTC through share sales as supportive of the per-share thesis, while bears warn that dilution and weak price action could keep the stock under pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Veru (VERU) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?

Equity

Veru will evaluate enobosarm alongside Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

Others

Veru (VERU) Q1 2026 Earnings Call Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

A Look Ahead: Veru's Earnings Forecast

Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm 

VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. The company was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1971 and is headquartered in Miami, FL.

Veru Inc

Neutral Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

VERU Veru Inc